Galectin expression in urological cancer: Diagnostic, prognostic and therapeutic potential;Galectin-Expression an urologischen Tumoren: Diagnostisches, prognostisches und therapeutisches Potential

Urologe - Ausgabe A

Volumn 49, Issue 3, 2010, Pages 387-391

  Waalkes, S ^a   Merseburger, A S ^a   Simon, A ^a   Serth, J ^a   Kuczyk, M A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biomarker; Galectins; Urological cancer

Indexed keywords

GALECTIN; GALECTIN 1; GALECTIN 3; GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

APOPTOSIS; BIOLOGICAL ACTIVITY; BLADDER TUMOR; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CLEAR CELL CARCINOMA; EXTRACELLULAR SPACE; INTRACELLULAR SPACE; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; URINARY TRACT CANCER;

FEMALE; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 77952236019     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-2175-1     Document Type: Review

References (47)

1. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol 218:12-20
2. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90(2):162-173
3. Leffler H, Carlsson S, Hedlund M et al (2004) Introduction to galectins. Glycoconj J 19(7-9):433-440
4. Leffler H (2001) Galectins structure and function-a synopsis. Results Probl Cell Differ 33:57-83
5. Cooper DN, Barondes SH (1999) God must love galectins; he made so many of them. Glycobiology 9(10):979-984
6. Barondes SH, Castronovo V, Cooper DN et al (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76(4):597-598
7. Cooper DN, Boulianne RP, Charlton S et al (1997) Fungal galectins, sequence and specificity of two isolectins from Coprinus cinereus. J Biol Chem 272(3):1514-1521
8. Wells V, Mallucci L (1991) Identification of an autocrine negative growth factor: mouse beta-galactoside-binding protein is a cytostatic factor and cell growth regulator. Cell 64(1):91-97
9. Adams L, Scott GK, Weinberg CS (1996) Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1312(2):137-144
10. Yamaoka A, Kuwabara I, Frigeri LG, Liu FT (1995) A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 154(7):3479-3487
11. Poirier F, Timmons PM, Chan CT et al (1992) Expression of the L14 lectin during mouse embryogenesis suggests multiple roles during preand post-implantation development. Development 115(1):143-155
12. Raz A, Lotan R (1987) Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 6(3):433-452
13. Bresalier RS, Mazurek N, Sternberg LR et al (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115(2):287-296
14. Rabinovich GA, Iglesias MM, Modesti NM et al (1998) Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 160(10):4831-4840
15. Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Apoptosis of T cells mediated by galectin-1. Nature 378(6558):736-739
16. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93(13):6737-6742
17. Wada J, Ota K, Kumar A et al (1997) Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest 99(10):2452-2461
18. Dunphy JL, Barcham GJ, Bischof RJ et al (2002) Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J Biol Chem 277(17):14916-14924
19. Iurisci I, Tinari N, Natoli C et al (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6(4):1389-1393
20. Inohara H, Honjo Y, Yoshii T et al (1999) Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85(11):2475-2484
21. Nangia-Makker P, Honjo Y, Sarvis R et al (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156(3):899-909
22. Inohara H, Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11(6):527-532
23. Yoshii T, Fukumori T, Honjo Y et al (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277(9):6852-6857
24. Glinsky VV, Huflejt ME, Glinsky GV et al (2000) Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60(10):2584-2588
25. John CM, Leffler H, Kahl-Knutsson B et al (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9(6):2374-2383
26. Califice S, Castronovo V, Van Den Brule F (2004) Galectin-3 and cancer (Review). Int J Oncol 25(4):983-992
27. Castronovo V, Van Den Brule FA, Jackers P et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43-48
28. Brule FA van den, Buicu C, Berchuck A et al (1996) Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27(11):1185-1191
29. Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 26(6):637-642
30. Francois C, Velthoven R van, De Lathouwer O et al (1999) Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112(2):194-203
31. Young AN, Amin MB, Moreno CS et al (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158(5):1639-1651
32. Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287-1290
33. Pacis RA, Pilat MJ, Pienta KJ et al (2000) Decreased galectin-3 expression in prostate cancer. Prostate 44(2):118-123
34. Danguy A, Rorive S, Decaestecker C et al (2001) Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol 16(3):861-868
35. Poulakis V, Witzsch U, De Vries R et al (2001) A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 88(7):692-701
36. Sakaki M, Oka N, Nakanishi R et al (2008) Serum level of galectin-3 in human bladder cancer. J Med Invest 55(1-2):127-132
37. Cindolo L, Benvenuto G, Salvatore P et al (1999) galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84(1):39-43
38. Kramer MW, Kuczyk MA, Hennenlotter J et al (2008) Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 20(6):1403-1408
39. Matsui Y, Ueda S, Watanabe J et al (2007) Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res 67(3):1212-1220
40. Oka N, Takenaka Y, Raz A (2004) Galectins and urological cancer. J Cell Biochem 91(1):118-124
41. Brule FA van den, Waltregny D, Liu FT, Castronovo V (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89(4):361-367
42. Califice S, Castronovo V, Bracke M, Brule F van den (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23(45):7527-7536
43. Ellerhorst JA, Stephens LC, Nguyen T, Xu XC (2002) Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50(1):64-70
44. Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68(1):72-77
45. Fukumori T, Oka N, Takenaka Y et al (2006) Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66(6):3114-3119
46. Brule FA van den, Waltregny D, Castronovo V (2001) Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193(1):80-87
47. Su ZZ, Lin J, Shen R et al (1996) Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci USA 93(14):7252-7257